Ventyx Biosciences Past Earnings Performance
Past criteria checks 0/6
Ventyx Biosciences's earnings have been declining at an average annual rate of -36.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-36.1%
Earnings growth rate
49.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -54.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Nov 04Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
Jul 12Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
Jul 01Ventyx Pivots To Obesity Amid Transformation
Mar 12Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation
Feb 15Ventyx: Too Risky Right Now After Some Poor Data
Jan 18Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth
Sep 21Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Feb 20Ventyx Biosciences: Not Chasing This Rally
Sep 18We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Aug 19Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06
Aug 15Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals
Jun 29We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
May 06We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Jan 21Revenue & Expenses Breakdown
How Ventyx Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -153 | 32 | 134 |
| 30 Jun 24 | 0 | -171 | 32 | 153 |
| 31 Mar 24 | 0 | -193 | 33 | 174 |
| 31 Dec 23 | 0 | -193 | 32 | 176 |
| 30 Sep 23 | 0 | -181 | 32 | 164 |
| 30 Jun 23 | 0 | -158 | 30 | 140 |
| 31 Mar 23 | 0 | -125 | 27 | 106 |
| 31 Dec 22 | 0 | -108 | 25 | 88 |
| 30 Sep 22 | 0 | -91 | 21 | 71 |
| 30 Jun 22 | 0 | -73 | 17 | 56 |
| 31 Mar 22 | 0 | -69 | 13 | 51 |
| 31 Dec 21 | 0 | -85 | 9 | 58 |
| 30 Sep 21 | 0 | -84 | 5 | 46 |
| 30 Jun 21 | 0 | -79 | 3 | 37 |
| 31 Mar 21 | 0 | -65 | 1 | 29 |
| 31 Dec 20 | 0 | -28 | 1 | 6 |
Quality Earnings: VTYX is currently unprofitable.
Growing Profit Margin: VTYX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VTYX is unprofitable, and losses have increased over the past 5 years at a rate of 36.1% per year.
Accelerating Growth: Unable to compare VTYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: VTYX has a negative Return on Equity (-54.71%), as it is currently unprofitable.